Daewoong Pharmaceutical's self-developed SGLT2i ingredient, Enavogliflozin, combined with Metformin hydrochloride will be released in September. In particular, even though metformin hydrochloride is added, the price is the same as the existing single drug Envlo. This is related to the drug price calculation structure for combination drugs.

According to the industry on the 22nd, Daewoong Pharmaceutical's Envlomet SR 0.3/1000mg will be listed as a benefit at 611 won per party from the 1st of next month. This drug is a combination drug that combines metformin, an ingredient for treating diabetes, with Envlo, a new domestic SGLT2i drug released last May.